Zimbabwe has turned down a substantial American health deal worth $367m (272 million pounds) over five years over the United States' insistence on confidential data.
This move was revealed following a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesperson has since explained that the United States was requesting health data for scientific study and commercial purposes but refused to guarantee the benefits from future medical innovations.
"We will now turn to the challenging and unfortunate task of scaling back our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for more talks to secure a deal suitable to both sides so the nation's critical HIV treatment initiative can continue.
Broader Context
This rejection comes after a similar situation in Kenya, where a court halted a similar deal with the US following concerns were filed about the safety of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had managed aid for the US government, but Trump argued its spending was "inefficient" and his administration was pursuing direct bilateral deals to enhance openness and responsibility.
According to reports, 16 African countries have so far agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy through American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to provide its genetic material and health information for a long time, with no corresponding assurance of benefiting from any medical innovations – such as new medicines or tests – that could result from that shared data," Mangwana explained.
"Effectively, our country would provide the raw materials for medical research with no certainty that the resulting innovations would be available to our citizens should a new disease outbreak emerge."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting systems previously established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to manage potential pandemics.
"This framework is designed to guarantee that when a nation provides its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage ongoing discussions with our US partners on how future co-operation could be designed in a way that honours the sovereignty and interests of both nations."
Health Experts Reaction
Medical experts expressed it recognised the official position, but suggested that talks must proceed since much of the country's Aids initiatives depended on foreign aid.
"If technical issues arise, including those involving data governance or implementation frameworks, these can often be addressed via detailed discussion and negotiated safeguards," the group commented.
This impasse underscores the ongoing debate between accepting much-needed foreign assistance and protecting local interests in an increasingly data-driven world.